首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1743977篇
  免费   130786篇
  国内免费   5437篇
耳鼻咽喉   22223篇
儿科学   56684篇
妇产科学   47197篇
基础医学   246780篇
口腔科学   49795篇
临床医学   157272篇
内科学   343353篇
皮肤病学   39669篇
神经病学   134093篇
特种医学   64970篇
外国民族医学   248篇
外科学   262760篇
综合类   45092篇
现状与发展   6篇
一般理论   539篇
预防医学   128770篇
眼科学   41361篇
药学   128398篇
  59篇
中国医学   6754篇
肿瘤学   104177篇
  2021年   15323篇
  2019年   15204篇
  2018年   21792篇
  2017年   16860篇
  2016年   18020篇
  2015年   21023篇
  2014年   28978篇
  2013年   41160篇
  2012年   57434篇
  2011年   60181篇
  2010年   36024篇
  2009年   33478篇
  2008年   54878篇
  2007年   58062篇
  2006年   58113篇
  2005年   55095篇
  2004年   52707篇
  2003年   50034篇
  2002年   47882篇
  2001年   92202篇
  2000年   93942篇
  1999年   77242篇
  1998年   19974篇
  1997年   17504篇
  1996年   17615篇
  1995年   16920篇
  1994年   15433篇
  1993年   14181篇
  1992年   57482篇
  1991年   55340篇
  1990年   53037篇
  1989年   50809篇
  1988年   46186篇
  1987年   44985篇
  1986年   42278篇
  1985年   40032篇
  1984年   29390篇
  1983年   24947篇
  1982年   13949篇
  1979年   25564篇
  1978年   17592篇
  1977年   14935篇
  1976年   13904篇
  1975年   14581篇
  1974年   17643篇
  1973年   16958篇
  1972年   15681篇
  1971年   14464篇
  1970年   13437篇
  1969年   12525篇
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
101.
102.
目的 研究肿瘤基因图谱(the cancer genome atlas,TCGA)数据库中microRNA-301b(miR-301b)在478 例卵巢癌患者中的表达量与卵巢癌患者生存状况的关系。方法 对TCGA 数据库中478 例卵巢癌患者的miR-301b 表达量与生存状况进行分析,预测其靶基因及生物学活性。结果 miR-301b 高表达患者具有更长的生存时间, 是卵巢癌患者预后的保护因素(OS:P<0.001, DFS:P<0.05),综合3 个靶基因数据库的预测结果得到12 个靶基因,编码的蛋白多数与肿瘤的发生发展有关,其中靶基因TEA 结构域家族成员1(TEA domain family member 1,TEAD1) 与胞质多糖基化元件结合蛋白4(cytoplasmic polyadenylation element binding protein 4, CPEB4)的表达量与卵巢癌患者的预后相关(TEAD1:P<0.05,CPEB4:P<0.05)。结论 miR-301b 表达对卵巢癌患者的预后具有重要的意义,表现出抑癌因子的作用,对卵巢癌的预后评估和治疗具有重要的指导意义。  相似文献   
103.
目的探讨分析山东济宁地区自然人群幽门螺杆菌的流行病学特征,为防治提供参考。方法于2012-05/2013-05采集山东济宁市第一人民医院胃镜室就诊患者580例,采用14C-UBT检测法与血清幽门螺杆菌Ig G抗体ELISA法对所有研究对象的幽门螺杆菌感染情况进行检测,并结合相关问卷调查,分析其流行病学特征。结果该医院门诊患者幽门螺杆菌总感染率45.2%,其中男性感染率59.5%,女性感染率40.5%,不同性别感染幽门螺杆菌感染阳性率差异比较无统计学意义(P0.05);各年龄段幽门螺杆菌的感染率从31.4%~53.1%不等,农民、商人及工人幽门螺杆菌感染率分别为78.6%、70.7%、68.8%,高于其他职业,差异有统计学意义(P0.05),但各年龄段间幽门螺杆菌感染率的差异比较无统计学意义(P0.05)。幽门螺杆菌感染与吸烟、饮酒、家庭收入无关,差异无统计学意义(均P0.05),与个人饮食卫生习惯、家庭教育程度及职业有关,差异有统计学意义(P0.05)。结论山东济宁市某医院门诊患者幽门螺杆菌总感染率较高,其感染率与职业、个人及家庭生活习惯等有关。  相似文献   
104.
105.
106.
107.
108.
109.
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples.  相似文献   
110.
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号